- Home
- PBHC vs ABOS Comparison
PBHC vs ABOS Comparison
Compare PBHC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- ABOS
- Stock Information
- Founded
- PBHC 1859
- ABOS 1996
- Country
- PBHC United States
- ABOS United States
- Employees
- PBHC N/A
- ABOS N/A
- Industry
- PBHC Major Banks
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- PBHC Finance
- ABOS Health Care
- Exchange
- PBHC Nasdaq
- ABOS Nasdaq
- Market Cap
- PBHC 93.1M
- ABOS 85.4M
- IPO Year
- PBHC N/A
- ABOS 2021
- Fundamental
- Price
- PBHC $14.70
- ABOS $1.53
- Analyst Decision
- PBHC
- ABOS Strong Buy
- Analyst Count
- PBHC 0
- ABOS 3
- Target Price
- PBHC N/A
- ABOS $6.33
- AVG Volume (30 Days)
- PBHC 2.9K
- ABOS 270.7K
- Earning Date
- PBHC 07-30-2025
- ABOS 08-12-2025
- Dividend Yield
- PBHC 2.72%
- ABOS N/A
- EPS Growth
- PBHC N/A
- ABOS N/A
- EPS
- PBHC 0.28
- ABOS N/A
- Revenue
- PBHC $39,015,000.00
- ABOS N/A
- Revenue This Year
- PBHC N/A
- ABOS N/A
- Revenue Next Year
- PBHC N/A
- ABOS N/A
- P/E Ratio
- PBHC $52.37
- ABOS N/A
- Revenue Growth
- PBHC N/A
- ABOS N/A
- 52 Week Low
- PBHC $13.71
- ABOS $0.86
- 52 Week High
- PBHC $19.86
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- PBHC 49.58
- ABOS 58.73
- Support Level
- PBHC $14.40
- ABOS $1.35
- Resistance Level
- PBHC $14.70
- ABOS $1.46
- Average True Range (ATR)
- PBHC 0.19
- ABOS 0.11
- MACD
- PBHC 0.03
- ABOS 0.00
- Stochastic Oscillator
- PBHC 61.63
- ABOS 85.00
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.